Plural Hetero Atoms In The Hetero Ring Patents (Class 514/439)
-
Patent number: 7211592Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.Type: GrantFiled: September 13, 2004Date of Patent: May 1, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
-
Patent number: 7202366Abstract: Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.Type: GrantFiled: March 25, 2004Date of Patent: April 10, 2007Assignee: Theracos, Inc.Inventors: Bishwajit Nag, Debendranath Dey, Satyanarayana Medicherla, Partha Neogi
-
Patent number: 7115758Abstract: The invention relates to vitamin D derivatives of general formula I, process for their production, intermediate products of the process as well as the use for the production of pharmaceutical agents.Type: GrantFiled: November 26, 2002Date of Patent: October 3, 2006Assignee: Schering AGInventors: Andreas Steinmeyer, Katica Schwarz, Claudia Giesen, Martin Haberey, Marianne Fähnrich
-
Patent number: 7105552Abstract: Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.Type: GrantFiled: April 27, 2001Date of Patent: September 12, 2006Assignee: Theracos, Inc.Inventors: Bishwajit Nag, Debendranath Dey, Satyanarayana Medicherla, Partha Neogi
-
Patent number: 7030152Abstract: The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.Type: GrantFiled: August 31, 1999Date of Patent: April 18, 2006Assignee: The Brigham and Women's Hospital, Inc.Inventors: Paul Ridker, Charles H. Hennekens
-
Patent number: 6964980Abstract: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds.Type: GrantFiled: March 26, 2003Date of Patent: November 15, 2005Assignee: The Institute for Pharmaceutical Discovery, Inc.Inventors: Janet Sredy, Jorge Jacot
-
Patent number: 6958348Abstract: Disclosed is an anti-cancer compound represented by Structural Formula (I): The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).Type: GrantFiled: August 29, 2002Date of Patent: October 25, 2005Assignee: Synta Pharmaceuticals Corp.Inventors: Keizo Koya, Lijun Sun, Mitsunori Ono, Guiqing Liang, David James, Hao Li, Zhi-Qiang Xia
-
Patent number: 6906069Abstract: The invention provides compounds, compositions and methods for modulating the effects of LXR? in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR? function and as pharmacologically active agents. The compounds and compositions find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.Type: GrantFiled: January 6, 2000Date of Patent: June 14, 2005Assignee: Amgen Inc.Inventors: Leping Li, Julio C. Medina, Bei Shan
-
Patent number: 6897211Abstract: The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-?) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.Type: GrantFiled: November 18, 2002Date of Patent: May 24, 2005Assignee: Pliva-Istrazivacki Institut d.o.o.Inventors: Mladen Mercep, Milan Mesic, Dijana Pesic, Zeljko Zupanovic, Boska Hrvacic
-
Patent number: 6838477Abstract: Described herein are compounds related to lactacystin and lactacystin ?-lactone, pharmaceutical compositions containing the compounds, and methods of use.Type: GrantFiled: August 8, 2001Date of Patent: January 4, 2005Assignee: President and Fellows of Harvard CollegeInventors: Stuart L. Schreiber, Robert F. Standaert, Gabriel Fenteany, Timothy F. Jamison
-
Publication number: 20040180893Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.Type: ApplicationFiled: February 19, 2004Publication date: September 16, 2004Inventors: Jan Maria Rene Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
-
Patent number: 6762183Abstract: The invention relates to novel active compound combinations of certain cyclic ketoenols and certain active compounds that together have unexpectedly good insecticidal and acaricidal properties.Type: GrantFiled: October 7, 2002Date of Patent: July 13, 2004Assignee: Bayer AktiengesellschaftInventors: Reiner Fischer, Christoph Erdelen, Thomas Bretschneider
-
Publication number: 20040063669Abstract: The present invention relates to novel aryl-substituted S(O)m cycles of the formula (I) 1Type: ApplicationFiled: June 13, 2003Publication date: April 1, 2004Inventors: Reiner Fischer, Oliver Kretschik, Thomas Schenke, Ralf-Ingo Schenkel, Jurgen Wiedemann, Christoph Erdelen, Peter Losel, Mark Wilhelm Drewes, Dieter Feucht, Wolfram Andersch
-
Publication number: 20040063755Abstract: The invention provides novel &bgr;2 adrenergic receptor agonist compounds of formula (I): 1Type: ApplicationFiled: August 18, 2003Publication date: April 1, 2004Inventors: Edmund J. Moran, John R. Jacobsen, Michael R. Leadbetter, Matthew B. Nodwell, Sean G. Trapp, James Aggen, Timothy J. Church
-
Patent number: 6692557Abstract: An antifouling coating composition comprising a carrier and an antifouling agent belonging to the families of isothiazolones or furanones, wherein the composition is substantially non-toxic to a cultured marine or aquatic animal when applied to the animal; and uses of the antifouling composition to reduce or inhibit fouling of marine or aquatic animals and aquaculture apparatus.Type: GrantFiled: April 23, 2001Date of Patent: February 17, 2004Assignee: Unisearch LimitedInventors: Peter Canisius De Nys, Peter David Steinberg, Timothy Stuart Charlton, Victor Christov
-
Patent number: 6689372Abstract: The use of oxathiazolones of formula is described R1 is phenyl unsubstituted or substituted by one or more C1-C5 alkyl, hydroxyl, halogen substituents or by a 1,3,4-oxathiazol-2-one radical. in the antimicrobial treatment of surfaces. The compounds exhibit a pronounced action against pathogenic gram-positive and gram-negative bacteria, and also against yeasts and moulds.Type: GrantFiled: February 1, 2000Date of Patent: February 10, 2004Assignee: Ciba Specialty Chemicals CorporationInventors: Werner Hölzl, Marcel Schnyder
-
Patent number: 6682747Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.Type: GrantFiled: November 7, 2000Date of Patent: January 27, 2004Assignee: Boehringer Ingelheim Pharma KGInventors: Dietrich Türck, Veit Schmelmer
-
Patent number: 6677374Abstract: Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic compound comprising a nitrate ester, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: March 29, 2002Date of Patent: January 13, 2004Assignee: Queen's University at KingstonInventors: Gregory R. J. Thatcher, Brian M. Bennett, James N. Reynolds, Roland J. Boegman, Khem Jhamandas
-
Patent number: 6667346Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the toxic side effects of ionizing radiation. Administration of a radioprotective &agr;,&bgr; unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increase the dosage of anticancer radiation. In some instances, amelioration of toxicity following inadvertent radiation exposure may be mitigated with administration of &agr;,&bgr; unsaturated arylsulfone.Type: GrantFiled: February 28, 2002Date of Patent: December 23, 2003Assignees: Temple University - Of The Commonwealth System of Higher Education, Onconova Therapeutics, Inc.Inventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stephen C. Cosenza, Lawrence Helson
-
Patent number: 6664283Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.Type: GrantFiled: May 15, 2002Date of Patent: December 16, 2003Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe
-
Publication number: 20030229058Abstract: The invention provides novel &bgr;2 adrenergic receptor agonist compounds of formula (I): 1Type: ApplicationFiled: May 8, 2003Publication date: December 11, 2003Inventors: Edmund J. Moran, John R. Jacobsen, Michael R. Leadbetter, Matthew B. Nodwell, Sean G. Trapp, James Aggen, Timothy J. Church
-
Publication number: 20030203948Abstract: It is found out that compounds represented by the formula (I): 1Type: ApplicationFiled: February 27, 2003Publication date: October 30, 2003Inventors: Toshio Fujishita, Kenji Abe
-
Publication number: 20030191161Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydrobenzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.Type: ApplicationFiled: March 31, 2003Publication date: October 9, 2003Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
-
Patent number: 6620829Abstract: The invention relates to a method of treating non inflammatory cartilage damage by administering a GABA analog of Formula: and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 14, 2001Date of Patent: September 16, 2003Assignee: Warner-Lambert CompanyInventors: Denis Schrier, Howard Glenn Welgus, David Juergen Wustrow
-
Patent number: 6599903Abstract: Intermediate compounds having the formula wherein the substituents are defined as set forth in the disclosure.Type: GrantFiled: September 4, 2001Date of Patent: July 29, 2003Assignee: Societe de Conseils de Recherches d'Applications Scientifiques (S.C.R.A.S.)Inventors: Pierre Etienne Chabrier de Lassauniere, Serge Auvin, Dennis Bigg, Michel Auguet, Jeremiah Harnett
-
Publication number: 20030139376Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): 1Type: ApplicationFiled: October 22, 2002Publication date: July 24, 2003Applicant: Schering AktiengesellschaftInventors: John G. Bauman, William J. Guilford, John F. Parkinson, Werner Skuballa, Babu Subramanyam
-
Patent number: 6596745Abstract: Provided is a method of treating or ameliorating hypertension in an animal comprising administering an effective amount of a compound of formula I:Type: GrantFiled: May 30, 2002Date of Patent: July 22, 2003Assignee: Alteon, Inc.Inventor: Martin Gall
-
Patent number: 6586438Abstract: A low dose antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes in drug naive patients, which includes a combination of metformin (employed in a reduced amount (less than 800 mg metformin per day) compared to that employed in generally accepted medical practice) and at least one other antidiabetic agent such as a sulfonyl urea, for example, glyburide, which combination provides at least about substantially equivalent efficacy in treating diabetes in drug naive patients, as do antidiabetic formulations containing metformin employed in dosages prescribed in generally accepted medical practice for first line therapy in treating diabetes, but with substantially reduced side effects, such as hypoglycemia and/or gastrointestinal distress.Type: GrantFiled: November 3, 1999Date of Patent: July 1, 2003Assignee: Bristol-Myers Squibb Co.Inventor: Beth Anne Piper
-
Patent number: 6583172Abstract: Anticonvulsant derivatives useful in treating chronic neurodegenerative conditions are disclosed.Type: GrantFiled: March 30, 2000Date of Patent: June 24, 2003Inventor: Richard P. Shank
-
Patent number: 6555568Abstract: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds.Type: GrantFiled: December 1, 1999Date of Patent: April 29, 2003Assignee: Institute for Pharmaceutical Discovery, L.L.C.Inventors: Janet Sredy, Jorge Jacot
-
Publication number: 20030072746Abstract: A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one glutaminase inhibitor. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.Type: ApplicationFiled: September 13, 2002Publication date: April 17, 2003Inventor: Kenneth E. Miller
-
Patent number: 6531485Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: December 16, 1999Date of Patent: March 11, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul A. DaSilva-Jardine
-
Publication number: 20030008895Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: ApplicationFiled: December 16, 1999Publication date: January 9, 2003Inventors: KIMBERLY O CAMERON, PAUL A. DASILVA-JARDINE
-
Patent number: 6495523Abstract: Anticonvulsant compounds of the general formula I: where X, R1, R2, R3, R4, R5, and R6 are as herein defined; are useful in treating acute ischemia-induced neurodegeneration, such as occurs during and after stroke, head trauma, spinal injury, non-fatal cardiac arrest, or major surgical procedures. Furthermore, pharmaceutical compositions containing a compound of formula I as well as methods for their use are disclosed.Type: GrantFiled: July 20, 2000Date of Patent: December 17, 2002Assignee: Ortho McNeil-Pharmaceutical, Inc.Inventors: Michael J. Costanzo, Bruce E. Maryanoff, Richard P. Shank
-
Patent number: 6436985Abstract: The present application describes disubstituted pyrazolines and triazolines of formulae I and II: or pharmaceutically acceptable salt forms thereof, wherein one of M1 and M2 maybe N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.Type: GrantFiled: December 1, 2000Date of Patent: August 20, 2002Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Donald J. P. Pinto
-
Patent number: 6410579Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.Type: GrantFiled: February 14, 2001Date of Patent: June 25, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
-
Patent number: 6410574Abstract: The present invention relates to a fungicidal composition obtained by mixing a 1,2,3-thiadiazole derivative of general formula (I) useful as a plant disease controller with at least one fungicide selected from the compounds having a fungicidal activity against plant diseases, and to a method for using the same: wherein R1 is hydrogen, alkyl or cycloalkyl and R2 is CO—Y—R3, wherein Y is O, S, NR4 or the like and R3 is hydrogen, alkyl, phenyl, 5- or 6-membered heterocycle or the like.Type: GrantFiled: July 28, 1999Date of Patent: June 25, 2002Assignee: Nihon Nohyaku Co., Ltd.Inventors: Tsutomu Nishiguchi, Tsuyoshi Takemoto, Sohkichi Tajima, Yoshinobu Yamamoto
-
Patent number: 6395724Abstract: Disclosed are multibinding compounds which inhibit cyclooxygenase-2 (COX-2), an enzyme which catalyzes the first committed step in the biosynthesis of prostaglandins. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is a moiety capable of binding to COX-2. The multibinding compounds of this invention are useful in the treatment inflammation, pain, fever and the like.Type: GrantFiled: June 7, 1999Date of Patent: May 28, 2002Assignee: Advanced Medicine, Inc.Inventors: J. Kevin Judice, Deborah L. Higgins, John H. Griffin
-
Patent number: 6369097Abstract: The present invention provides new methods for the treatment of viral hepatitis C involving the administration of vitamin E and other compounds with antioxidant properties. Treatment with high doses of vitamin E is effective in treating chronic hepatitis C in patients refractory to interferon. In addition, new methods are described for the treatment of hepatic fibrosis and hepatic conditions manifesting hepatic fibrosis involving the administration of butylated hydroxytoluene and a metabolite of pentoxifylline, 1-[3-carboxypropyl]-3,7-dimethylxanthine. Furthermore, new methods are described for the treatment and prevention of hepatic disorders involving the use of 2,6-di-tert-butylphenol derivatives.Type: GrantFiled: November 28, 2000Date of Patent: April 9, 2002Assignee: The Regents of the University of CaliforniaInventor: Mario Chojkier
-
Patent number: 6365579Abstract: Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic compound comprising a nitrate ester, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: May 10, 2001Date of Patent: April 2, 2002Assignee: Queen's University at KingstonInventors: Gregory R. J. Thatcher, Brian M. Bennett, James N. Reynolds, Roland J. Boegman, Khem Jhamandas
-
Patent number: 6344485Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.Type: GrantFiled: June 18, 1999Date of Patent: February 5, 2002Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker
-
Patent number: 6344476Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.Type: GrantFiled: May 22, 1998Date of Patent: February 5, 2002Assignee: Bayer CorporationInventors: Gerald Ranges, William Scott, Michael Bombara, Deborah Rauner, Aniko Redman, Roger Smith, Holger Paulsen, David Gunn, Jinshan Chen, Joel Renick
-
Patent number: 6335358Abstract: Compounds related to lactacystin and lactacystin &bgr;-lactone, pharmaceutical compositions containing the compounds, and methods of use.Type: GrantFiled: April 12, 1995Date of Patent: January 1, 2002Assignee: President and Fellows of Harvard CollegeInventors: Gabriel Fenteany, Timothy F. Jamison, Stuart L. Schreiber, Robert F. Standaert
-
Patent number: 6333316Abstract: Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.Type: GrantFiled: August 18, 1999Date of Patent: December 25, 2001Assignee: Merck & Co., Inc.Inventors: Anastasia G. Daifotis, Arthur C. Santora, II, A. John Yates
-
Patent number: 6323236Abstract: Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others. The present invention comprises methods for the treatment or prevention of ICD's using a class of sulfamates of the following formula: wherein X is CH2 or oxygen, and R1, R2, R3, R4 and R5 are as herein defined. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention are also disclosed.Type: GrantFiled: February 18, 2000Date of Patent: November 27, 2001Assignee: University of CincinnatiInventor: Susan McElroy
-
Patent number: 6313155Abstract: A method and composition for treating macular disorders. A pharmologically effective amount of a carbonic anhydrase inhibitor is combined with a pharmologically effective amount of an ocular hypotensive agent sufficient to improve visual function.Type: GrantFiled: September 6, 2000Date of Patent: November 6, 2001Assignee: Board of Regents, The University of Texas SystemInventor: William E. Sponsel
-
Patent number: 6313152Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.Type: GrantFiled: September 7, 1999Date of Patent: November 6, 2001Assignees: Athena Neurosciences, Inc., Eli Lilly and CompanyInventors: Jing Wu, Eugene D. Thorsett, Jeffrey S. Nissen, Thomas E. Mabry, Lee H. Latimer, Varghese John, Lawrence Y. Fang, James E. Audia
-
Patent number: 6306892Abstract: The present invention is directed to compound of the formula I: wherein R1, R2, R3, R4, R 5, X, Y, and are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.Type: GrantFiled: June 21, 2000Date of Patent: October 23, 2001Assignees: Agouron Pharmaceuticals, Inc., Syntex Inc.Inventors: Steven L. Bender, Arlindo L. Castelhano, Wesley K. M. Chong, Melwyn A. Abreo, Roland J. Billedeau, Jian Jeffrey Chen, Judith G. Deal
-
Patent number: 6300325Abstract: This invention relates to novel benzo-2-triazole substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO&agr;, GRO&bgr;, GRO&ggr; and NAP-2 mediated diseases.Type: GrantFiled: July 9, 1999Date of Patent: October 9, 2001Assignee: SmithKline Beecham CorporationInventors: Katherine L. Widdowson, Melvin C. Rutledge
-
Publication number: 20010023254Abstract: Impulse Control Disorders (ICD's) are characterized by harmful behaviors performed in response to irresistible impulses. The essential feature of an ICD is the failure to resist an impulse, drive, or temptation and to perform an act that is harmful to the person or to others.Type: ApplicationFiled: February 18, 2000Publication date: September 20, 2001Inventor: Susan L. McElroy